Back to SYRE
GOLDMAN SACHS GROUP INC → SYRE
GOLDMAN SACHS GROUP INC SYRE Position History
Spyre Therapeutics, Inc. • Healthcare
Quarters held
21
Latest value
$350K
Q3 2026
Peak value
$72.7M
First seen
Q2 2025
Dollar value over time
Show data table
| Period | Position value |
|---|---|
| Q2 2025 | $5.4M |
| Q2 2025 | $2.4M |
| Q3 2025 | $3.4M |
| Q3 2025 | $2.2M |
| Q4 2025 | $3.7M |
| Q4 2025 | $5.3M |
| Q4 2025 | $5.3M |
| Q4 2025 | $3.7M |
| Q1 2026 | $7.7M |
| Q1 2026 | $6M |
| Q2 2026 | $72.7M |
| Q2 2026 | $56.4M |
| Q2 2026 | $750K |
| Q2 2026 | $212K |
| Q2 2026 | $474K |
| Q2 2026 | $326K |
| Q2 2026 | $382K |
| Q3 2026 | $55M |
| Q3 2026 | $51.4M |
| Q3 2026 | $447K |
| Q3 2026 | $350K |
Quarter-by-quarter history
Every disclosed snapshot of the position
| Quarter | Value | Shares | % Portfolio | Change |
|---|---|---|---|---|
| Q3 2026 | $350K | 3.9K | — | — |
| Q3 2026 | $447K | 5.0K | — | — |
| Q3 2026 | $51.4M | 577.7K | — | — |
| Q3 2026 | $55M | 618.1K | — | — |
| Q2 2026 | $382K | 4.3K | — | — |
| Q2 2026 | $326K | 3.7K | — | — |
| Q2 2026 | $474K | 5.3K | — | — |
| Q2 2026 | $212K | 2.4K | — | — |
| Q2 2026 | $750K | 8.4K | — | — |
| Q2 2026 | $56.4M | 634.9K | — | — |
| Q2 2026 | $72.7M | 819.0K | — | — |
| Q1 2026 | $6M | 118.2K | — | — |
| Q1 2026 | $7.7M | 151.8K | — | — |
| Q4 2025 | $3.7M | 112.6K | — | — |
| Q4 2025 | $5.3M | 162.4K | — | — |
| Q4 2025 | $5.3M | 162.4K | — | — |
| Q4 2025 | $3.7M | 112.6K | — | — |
| Q3 2025 | $2.2M | 128.9K | — | — |
| Q3 2025 | $3.4M | 200.7K | — | — |
| Q2 2025 | $2.4M | 163.5K | — | — |
| Q2 2025 | $5.4M | 359.9K | — | — |
Other funds holding SYRE
$809.9M
$795.4M
$430.1M
$383.5M
$377.5M
$348.1M